Featured Research

from universities, journals, and other organizations

Breast Cancer Growth Regulator Holds Promise For More Targeted Treatment

Date:
July 6, 2005
Source:
Yale University
Summary:
Researchers at Yale School of Medicine have discovered the breast cancer growth regulator sEGFR, which may be a useful tool in monitoring a patient's responsiveness to treatment with the drug letrozole. Published in a recent issue of the American Association of Cancer Researcher's journal Cancer Research, the study focused on how decreased concentrations of sEGFR can indicate the effectiveness of letrozole.

Researchers at Yale School of Medicine have discovered the breast cancer growth regulator sEGFR, which may be a useful tool in monitoring a patient's responsiveness to treatment with the drug letrozole.

Published in a recent issue of the American Association of Cancer Researcher's journal Cancer Research, the study focused on how decreased concentrations of sEGFR can indicate the effectiveness of letrozole.

In women with postmenopausal breast cancer, the hormone estrogen often stimulates tumor growth. Letrozole, which is currently used in breast cancer therapy, stops the local production of estrogen, therefore reducing tumor growth. To monitor the effectiveness of this drug's reduction in tumor growth, estrogen levels are measured. In postmenopausal women with breast cancer, estrogen can be difficult to measure because the levels are already quite low. The Yale team, led by Nita J. Maihle, professor in the Department of Obstetrics, Gynecology & Reproductive Sciences, discovered sEGFR, another regulator of breast cancer growth that can be used to measure responsiveness to treatment.

Maihle and her colleagues collected blood samples from postmenopausal women with metastatic breast cancer before treatment with letrozole and then one month and three months after letrozole therapy. The team measured sEGFR concentrations in these blood samples and found that after one month of letrozole therapy, sEGFR decreased in 73 percent of patients and after three months of letrozole therapy, sEGFR concentrations decreased in 76 percent of patients when compared to pretreatment levels.

"Unfortunately, the number of patients (43) involved in this study was not large enough to evaluate how these changes in sEGFR levels predict a patient's cancer progression or survival," said Maihle. "Since the FDA recently approved letrozole for the treatment of breast cancer, larger studies are needed to determine its clinical utility."

"Ultimately, we hope to provide the most effective ways to determine who will respond to this new breast cancer therapy," added Maihle, who is also affiliated with Yale Cancer Center.

Other authors on the study included Jacqueline M. Lafky, Andre T. Baron, Elsa M. Cora, David W. Hillman, Vera J. Suman, Edith A. Perez and James N. Ingle.

###

Citation: Cancer Research 65, 3059-3062, (April 15, 2005).


Story Source:

The above story is based on materials provided by Yale University. Note: Materials may be edited for content and length.


Cite This Page:

Yale University. "Breast Cancer Growth Regulator Holds Promise For More Targeted Treatment." ScienceDaily. ScienceDaily, 6 July 2005. <www.sciencedaily.com/releases/2005/07/050706002151.htm>.
Yale University. (2005, July 6). Breast Cancer Growth Regulator Holds Promise For More Targeted Treatment. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2005/07/050706002151.htm
Yale University. "Breast Cancer Growth Regulator Holds Promise For More Targeted Treatment." ScienceDaily. www.sciencedaily.com/releases/2005/07/050706002151.htm (accessed July 25, 2014).

Share This




More Health & Medicine News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

AFP (July 24, 2014) A so-called drugs rehab 'clinic' is closed down in Pakistan after police find scores of ‘patients’ chained up alleging serial abuse. Duration 03:05 Video provided by AFP
Powered by NewsLook.com
Too Few Teens Receiving HPV Vaccination, CDC Says

Too Few Teens Receiving HPV Vaccination, CDC Says

Newsy (July 24, 2014) The Centers for Disease Control and Prevention is blaming doctors for the low number of children being vaccinated for HPV. Video provided by Newsy
Powered by NewsLook.com
New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins